Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02570854 · ClinicalTrials.gov registry record · Phase 1
A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02570854 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT02570854, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The study will assess the safety, tolerability and efficacy of CSJ137 in chronic hemodialysis patients. It is hypothesized that treatment with CSJ137 may improve the level of hemoglobin in patients on chronic hemodialysis with iron-restricted anemia while reducing the need for dosing with erythropoietin and intravenous iron in these patients.
Interventions
- DRUG Placebo
- BIOLOGICAL CSJ137
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-09-22 |
| Est. Completion | 2020-05-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02570854
The ClinicalTrials.gov registry entry for NCT02570854 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02570854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02570854 about?
NCT02570854 is a clinical study titled "A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients". The study will assess the safety, tolerability and efficacy of CSJ137 in chronic hemodialysis patients. It is hypothesized that treatment with CSJ137 may improve the level of hemoglobin in patients on chronic hemodialysis with iron-restricted anemia while reducing the need for dosing with erythropoi...
What is the current status of trial NCT02570854?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2015-09-22. Estimated completion is 2020-05-13.
What interventions are being tested in trial NCT02570854?
The interventions under investigation include: Placebo (DRUG), CSJ137 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02570854?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.